Zeria

Otsuka and Aurinia's Lupkynis granted EC approval as active lupus nephritis treatment

Otsuka initiated a partnership and licensing agreement with Aurinia in December 2020 for the development and commercialisation of Lupkynis for the treatment of LN in the EU, the UK, Japan, Russia,

Bristol Myers Squibb’s Opdivo shows promise as adjuvant melanoma treatment

EU, the US, Japan and China.

Novavax’s COVID-19 vaccine candidate receives EC approval for use as a booster

Nuvaxovid has also been approved in Japan, Australia and New Zealand as a booster in adults aged 18 years and older, and is actively under review in other markets.

AstraZeneca’s Imfinzi plus chemotherapy shows promise for advanced biliary tract cancer

Regulatory applications are also currently under review in Europe, Japan and several other countries based on the TOPAZ-1 results, the company outlined. ... Approximately 50, 000 people in Europe, the US and Japan and around 210, 000 people worldwide are

Novartis and BeiGene announce positive phase 3 trial results for hepatocellular carcinoma treatment

Through a collaboration and licence agreement with BeiGene in January 2021, Novartis has the rights to develop, manufacture and commercialise tislelizumab in Europe, North America and Japan.

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]